In addition, a recent large Danish cohort study with more than 13,000 women enrolled showed an association between obesity and an increased risk of BC recurrence among postmenopausal patients with hormone-receptor-positive early-stage BC treated with aromatase inhibitors [6]. Here, NR4A1 is linked to obesity disorder.